BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 32558308)

  • 21. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome.
    Devaux CA; Rolain JM; Raoult D
    J Microbiol Immunol Infect; 2020 Jun; 53(3):425-435. PubMed ID: 32414646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.
    Liu Z; Xiao X; Wei X; Li J; Yang J; Tan H; Zhu J; Zhang Q; Wu J; Liu L
    J Med Virol; 2020 Jun; 92(6):595-601. PubMed ID: 32100877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural and functional modelling of SARS-CoV-2 entry in animal models.
    Brooke GN; Prischi F
    Sci Rep; 2020 Sep; 10(1):15917. PubMed ID: 32985513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition.
    Grant OC; Montgomery D; Ito K; Woods RJ
    Sci Rep; 2020 Sep; 10(1):14991. PubMed ID: 32929138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular simulation of SARS-CoV-2 spike protein binding to pangolin ACE2 or human ACE2 natural variants reveals altered susceptibility to infection.
    Wang J; Xu X; Zhou X; Chen P; Liang H; Li X; Zhong W; Hao P
    J Gen Virol; 2020 Sep; 101(9):921-924. PubMed ID: 32538738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms.
    Ali A; Vijayan R
    Sci Rep; 2020 Aug; 10(1):14214. PubMed ID: 32848162
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.
    Yang J; Petitjean SJL; Koehler M; Zhang Q; Dumitru AC; Chen W; Derclaye S; Vincent SP; Soumillion P; Alsteens D
    Nat Commun; 2020 Sep; 11(1):4541. PubMed ID: 32917884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor.
    Zhao P; Praissman JL; Grant OC; Cai Y; Xiao T; Rosenbalm KE; Aoki K; Kellman BP; Bridger R; Barouch DH; Brindley MA; Lewis NE; Tiemeyer M; Chen B; Woods RJ; Wells L
    Cell Host Microbe; 2020 Oct; 28(4):586-601.e6. PubMed ID: 32841605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19.
    Zhang S; Liu Y; Wang X; Yang L; Li H; Wang Y; Liu M; Zhao X; Xie Y; Yang Y; Zhang S; Fan Z; Dong J; Yuan Z; Ding Z; Zhang Y; Hu L
    J Hematol Oncol; 2020 Sep; 13(1):120. PubMed ID: 32887634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates.
    Damas J; Hughes GM; Keough KC; Painter CA; Persky NS; Corbo M; Hiller M; Koepfli KP; Pfenning AR; Zhao H; Genereux DP; Swofford R; Pollard KS; Ryder OA; Nweeia MT; Lindblad-Toh K; Teeling EC; Karlsson EK; Lewin HA
    Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22311-22322. PubMed ID: 32826334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice.
    Bao L; Deng W; Huang B; Gao H; Liu J; Ren L; Wei Q; Yu P; Xu Y; Qi F; Qu Y; Li F; Lv Q; Wang W; Xue J; Gong S; Liu M; Wang G; Wang S; Song Z; Zhao L; Liu P; Zhao L; Ye F; Wang H; Zhou W; Zhu N; Zhen W; Yu H; Zhang X; Guo L; Chen L; Wang C; Wang Y; Wang X; Xiao Y; Sun Q; Liu H; Zhu F; Ma C; Yan L; Yang M; Han J; Xu W; Tan W; Peng X; Jin Q; Wu G; Qin C
    Nature; 2020 Jul; 583(7818):830-833. PubMed ID: 32380511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
    Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
    Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies.
    Vargas-Alarcón G; Posadas-Sánchez R; Ramírez-Bello J
    Life Sci; 2020 Nov; 260():118313. PubMed ID: 32835700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of
    Strafella C; Caputo V; Termine A; Barati S; Gambardella S; Borgiani P; Caltagirone C; Novelli G; Giardina E; Cascella R
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32635188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural basis of receptor recognition by SARS-CoV-2.
    Shang J; Ye G; Shi K; Wan Y; Luo C; Aihara H; Geng Q; Auerbach A; Li F
    Nature; 2020 May; 581(7807):221-224. PubMed ID: 32225175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated.
    Wambier CG; Goren A
    J Am Acad Dermatol; 2020 Jul; 83(1):308-309. PubMed ID: 32283245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection.
    Rathnasinghe R; Strohmeier S; Amanat F; Gillespie VL; Krammer F; García-Sastre A; Coughlan L; Schotsaert M; Uccellini MB
    Emerg Microbes Infect; 2020 Dec; 9(1):2433-2445. PubMed ID: 33073694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.
    Kreye J; Reincke SM; Kornau HC; Sánchez-Sendin E; Corman VM; Liu H; Yuan M; Wu NC; Zhu X; Lee CD; Trimpert J; Höltje M; Dietert K; Stöffler L; von Wardenburg N; van Hoof S; Homeyer MA; Hoffmann J; Abdelgawad A; Gruber AD; Bertzbach LD; Vladimirova D; Li LY; Barthel PC; Skriner K; Hocke AC; Hippenstiel S; Witzenrath M; Suttorp N; Kurth F; Franke C; Endres M; Schmitz D; Jeworowski LM; Richter A; Schmidt ML; Schwarz T; Müller MA; Drosten C; Wendisch D; Sander LE; Osterrieder N; Wilson IA; Prüss H
    Cell; 2020 Nov; 183(4):1058-1069.e19. PubMed ID: 33058755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.